The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis
infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic
bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent
in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current
understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria.
Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate
the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development.
In this light, we also summarize recent progress made in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design and inhibitors.
Rights & PermissionsPrintExport